Therapeutic readthrough strategy for suppression of nonsense mutations in Duchenne muscular dystrophy

Masataka Shiozuka, Ryoichi Matsuda

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Effective treatment for Duchenne muscular dystrophy (DMD) is currently unavailable. Readthrough of disease-causing premature termination codons might alleviate the symptoms of genetic diseases caused by nonsense mutations. Several ribosome-binding compounds, including selective antibiotics and synthetic novel small molecules, induce translational readthrough, restoring full-length functional proteins. Here in this innovative therapeutic strategy has been summarized with a focus on DMD. We have previously reported that negamycin restored dystrophin expression with less toxicity than gentamicin in mdx mice. To explore more potent readthrough inducers, we established the transgenic mouse called READ (readthrough evaluation and assessment by dural receptor) for readthrough-specific detection. Using READ mice, we discovered drug candidates, including sterically negamycin-like small molecules and aminoglycoside derivatives. The newly developed small molecules induced dose-dependent readthrough with greater potency than ataluren in vitro and promoted the expression of dystrophin and reduction in serum creatine kinase activity in mdx mice. Moreover, the aminoglycoside derivative restored both dystrophin protein and contractile function of mdx skeletal muscles with appreciably higher readthrough activity and lower toxicity than that of gentamicin. Furthermore, we confirmed the efficacy of a thioglycolate-based depilatory agent to enhance the topical delivery of skin-impermeable drugs, including aminoglycosides. These promising new chemotherapeutic agents with beneficial effects on readthrough action, lower toxicity, and transdermal delivery may have significant value in treating or preventing genetic diseases caused by nonsense mutations.

Original languageEnglish
Pages (from-to)1253-1260
Number of pages8
JournalBrain and Nerve
Volume63
Issue number11
Publication statusPublished - Nov 1 2011

Fingerprint

Dystrophin
Duchenne Muscular Dystrophy
Nonsense Codon
Aminoglycosides
Inbred mdx Mouse
Inborn Genetic Diseases
Gentamicins
Thioglycolates
Contractile Proteins
Creatine Kinase
Ribosomes
Pharmaceutical Preparations
Transgenic Mice
Skeletal Muscle
Therapeutics
Anti-Bacterial Agents
Skin
Serum
Proteins
negamycin

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Therapeutic readthrough strategy for suppression of nonsense mutations in Duchenne muscular dystrophy. / Shiozuka, Masataka; Matsuda, Ryoichi.

In: Brain and Nerve, Vol. 63, No. 11, 01.11.2011, p. 1253-1260.

Research output: Contribution to journalReview article

@article{e5d7af6e94904fdbb99f6636d6d10e13,
title = "Therapeutic readthrough strategy for suppression of nonsense mutations in Duchenne muscular dystrophy",
abstract = "Effective treatment for Duchenne muscular dystrophy (DMD) is currently unavailable. Readthrough of disease-causing premature termination codons might alleviate the symptoms of genetic diseases caused by nonsense mutations. Several ribosome-binding compounds, including selective antibiotics and synthetic novel small molecules, induce translational readthrough, restoring full-length functional proteins. Here in this innovative therapeutic strategy has been summarized with a focus on DMD. We have previously reported that negamycin restored dystrophin expression with less toxicity than gentamicin in mdx mice. To explore more potent readthrough inducers, we established the transgenic mouse called READ (readthrough evaluation and assessment by dural receptor) for readthrough-specific detection. Using READ mice, we discovered drug candidates, including sterically negamycin-like small molecules and aminoglycoside derivatives. The newly developed small molecules induced dose-dependent readthrough with greater potency than ataluren in vitro and promoted the expression of dystrophin and reduction in serum creatine kinase activity in mdx mice. Moreover, the aminoglycoside derivative restored both dystrophin protein and contractile function of mdx skeletal muscles with appreciably higher readthrough activity and lower toxicity than that of gentamicin. Furthermore, we confirmed the efficacy of a thioglycolate-based depilatory agent to enhance the topical delivery of skin-impermeable drugs, including aminoglycosides. These promising new chemotherapeutic agents with beneficial effects on readthrough action, lower toxicity, and transdermal delivery may have significant value in treating or preventing genetic diseases caused by nonsense mutations.",
author = "Masataka Shiozuka and Ryoichi Matsuda",
year = "2011",
month = "11",
day = "1",
language = "English",
volume = "63",
pages = "1253--1260",
journal = "Brain and Nerve",
issn = "1881-6096",
publisher = "Igaku-Shoin Ltd",
number = "11",

}

TY - JOUR

T1 - Therapeutic readthrough strategy for suppression of nonsense mutations in Duchenne muscular dystrophy

AU - Shiozuka, Masataka

AU - Matsuda, Ryoichi

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Effective treatment for Duchenne muscular dystrophy (DMD) is currently unavailable. Readthrough of disease-causing premature termination codons might alleviate the symptoms of genetic diseases caused by nonsense mutations. Several ribosome-binding compounds, including selective antibiotics and synthetic novel small molecules, induce translational readthrough, restoring full-length functional proteins. Here in this innovative therapeutic strategy has been summarized with a focus on DMD. We have previously reported that negamycin restored dystrophin expression with less toxicity than gentamicin in mdx mice. To explore more potent readthrough inducers, we established the transgenic mouse called READ (readthrough evaluation and assessment by dural receptor) for readthrough-specific detection. Using READ mice, we discovered drug candidates, including sterically negamycin-like small molecules and aminoglycoside derivatives. The newly developed small molecules induced dose-dependent readthrough with greater potency than ataluren in vitro and promoted the expression of dystrophin and reduction in serum creatine kinase activity in mdx mice. Moreover, the aminoglycoside derivative restored both dystrophin protein and contractile function of mdx skeletal muscles with appreciably higher readthrough activity and lower toxicity than that of gentamicin. Furthermore, we confirmed the efficacy of a thioglycolate-based depilatory agent to enhance the topical delivery of skin-impermeable drugs, including aminoglycosides. These promising new chemotherapeutic agents with beneficial effects on readthrough action, lower toxicity, and transdermal delivery may have significant value in treating or preventing genetic diseases caused by nonsense mutations.

AB - Effective treatment for Duchenne muscular dystrophy (DMD) is currently unavailable. Readthrough of disease-causing premature termination codons might alleviate the symptoms of genetic diseases caused by nonsense mutations. Several ribosome-binding compounds, including selective antibiotics and synthetic novel small molecules, induce translational readthrough, restoring full-length functional proteins. Here in this innovative therapeutic strategy has been summarized with a focus on DMD. We have previously reported that negamycin restored dystrophin expression with less toxicity than gentamicin in mdx mice. To explore more potent readthrough inducers, we established the transgenic mouse called READ (readthrough evaluation and assessment by dural receptor) for readthrough-specific detection. Using READ mice, we discovered drug candidates, including sterically negamycin-like small molecules and aminoglycoside derivatives. The newly developed small molecules induced dose-dependent readthrough with greater potency than ataluren in vitro and promoted the expression of dystrophin and reduction in serum creatine kinase activity in mdx mice. Moreover, the aminoglycoside derivative restored both dystrophin protein and contractile function of mdx skeletal muscles with appreciably higher readthrough activity and lower toxicity than that of gentamicin. Furthermore, we confirmed the efficacy of a thioglycolate-based depilatory agent to enhance the topical delivery of skin-impermeable drugs, including aminoglycosides. These promising new chemotherapeutic agents with beneficial effects on readthrough action, lower toxicity, and transdermal delivery may have significant value in treating or preventing genetic diseases caused by nonsense mutations.

UR - http://www.scopus.com/inward/record.url?scp=82155168549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155168549&partnerID=8YFLogxK

M3 - Review article

C2 - 22068478

AN - SCOPUS:82155168549

VL - 63

SP - 1253

EP - 1260

JO - Brain and Nerve

JF - Brain and Nerve

SN - 1881-6096

IS - 11

ER -